Lomecel-B medicinal signaling cells
Phase 2Biologic
Lomecel-B medicinal signaling cells is one of 6 biologic programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Hypoplastic Left Heart Syndrome
#DrugCompanyPhaseTrials
1Letairis
GileadApproved
Tepadina
Alnylam PharmaceuticalsPreclinical
Longeveron Mesenchymal Stem Cells
LLongeveron Inc.
Phase 2
Lomecel-B medicinal signaling cells
LLongeveron Inc.
Phase 2
Allo-Hmscs
JJoshua M Hare
Phase 1
C-Kit+ Cells
TThe University of Texas Health Science Center, Houston
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- LLongeveron Inc.